| Private Placement / Financing Transactions
Abridge: The company raised $250 million of Series D venture funding in a deal led by IVP and Elad Gil on February 19, 2005, putting the company’s pre-money valuation at $2.5 billion. CVS Health Ventures, NVentures, California Healthcare Foundation, CapitalG, Atria Ventures, SV Angel, K. Ventures, Redpoint Ventures, Lightspeed Venture Partners, Bessemer Venture Partners and Spark Capital also participated in the round. The company is a developer of a generative AI platform for clinical conversations to improve context and understanding.
VitalConnect: The company raised $100 million in a combination of debt and Series G venture funding in a deal led by Ally Bridge Group on February 19, 2025, putting the company’s pre-money valuation at $400 million. MVM Partners, EW Healthcare Partners, Revelation Partners and other undisclosed investors also participated in the round. The company is a developer of wearable biosensor technology designed to continuously monitor and record a patient’s vital signs.
OpenEvidence: The company raised $75 million of venture funding in a deal led by Sequoia Capital on February 19, 2025, putting the company’s pre-money valuation at $925 million. Other undisclosed investors also participated in the round. The company is a developer of an AI-powered information platform intended to organize medical knowledge and help doctors make decisions.
Atomwise: The company raised $45 million of Series C venture funding from Leaps by Bayer and other undisclosed investors on February 18, 2025. The company is an operator of an artificial intelligence-based biotechnology business intended to help discover and develop new medicines and agricultural compounds.
Endovascular Engineering: The company raised $42 million in Series B venture funding in a deal led by 415 Capital and S3 Ventures on February 18, 2025, putting the company’s pre-money valuation at $28 million. Philips Ventures, Panakes Partners, M&L Healthcare Investments, Santé Ventures, Inventure Group and other undisclosed investors also participated in the round. The company is a developer of a vascular thrombectomy technology designed for the management of ischemic stroke.
EG 427: The company raised EUR 27 million of Series B venture funding in a deal led by Andera Partners and Bpifrance on February 20, 2025. SCI Ventures also participated in the round. The company is a developer of a pinpoint gene therapy intended to cure spinal cord injury-related disorders.
Ceek Women’s Health: The company raised $20 million of venture funding from undisclosed investors on February 20, 2025. The company is a developer of medical devices for the delivery of gynecological care for women.
Hummingbird Healthcare: The company raised $20 million of Series B venture funding in a deal led by Health Velocity Capital on February 20, 2025. CU Healthcare Innovation Fund, University of Colorado Health and other undisclosed investors also participated in the round. The company is a developer of a healthcare technology platform designed to enhance patient access management and operational efficiency.
Avandra Imaging: The company raised $17.8 million of venture funding in a deal led by SpringRock Ventures and Aegis Ventures on February 17, 2025. Memorial Hermann Health System, Northwell Health, Kompass Digital, Greater Ventures, Scott Gaines and Mark Montoney also participated in the round. The company is a health technology business intended to help researchers and AI developers access anonymized imaging data.
Biolog: The company raised $16.1 million of venture funding from undisclosed investors on February 19, 2025. The company is a developer of cell analysis tools designed to identify cell phenotypes for early-stage detection of diseases.
Esperto Medical: The company raised $15.2 million of Series A venture funding in a deal led by Catalyst Health Ventures and BOLD Capital Partners on February 18, 2025, putting the company’s pre-money valuation at $16.8 million. Maverick Ventures, Wavemaker Three-Sixty Health, Freeflow Ventures, Rocket Fund, and other undisclosed investors also participated in the round. The company is a manufacturer of blood pressure measurement devices.
Cagent Vascular: The company raised $15 million of venture funding from Trinity Capital on February 20, 2025. The company is a developer of intravascular technology designed to treat diseased peripheral arteries.
Perceive Biotherapeutics: The company raised $15 million of Series B2 venture funding in a deal led by Deerfield Management on February 18, 2025, putting the company’s pre-money valuation at $154 million. Johnson & Johnson Innovation – JJDC, GV, Retinal Degeneration Fund, Catalio Capital Management, Braidwell and other undisclosed investors also participated in the round. The company is a developer of novel ophthalmic therapeutics designed to treat eye diseases.
Kestrel Therapeutics: The company raised $8 million of venture funding in the form of convertible debt from undisclosed investors on February 21, 2025. The company is a developer of oncological drugs designed to treat RAS-driven cancers and bring a new therapy to frequently mutated oncogenic targets.
Kytopen: The company raised $7 million of Series AA venture funding from undisclosed investors on February 20, 2025. The company is a developer of a genome engineering platform.
Berlin Heals: The company raised $7 million of venture funding from undisclosed investors on February 18, 2025. The company is a developer of a medical device designed for the treatment of cardiac arrest.
Rebel Medicine: The company raised $6 million of venture funding from Crocker Ventures and Central Texas Angel Network on February 21, 2025. The company is an operator of a preclinical-stage life sciences company that uses innovative drug delivery science to transform how therapeutics are delivered.
3Spine: The company raised $3 million of venture funding from undisclosed investors on February 21, 2025. The company is a developer of a joint replacement device designed to replace the lumbar spine.
Definitive Diagnostics: The company is in the process of raising venture funding as of February 18, 2025. The company is a developer of a proteomic technology platform designed to identify aggressive cancer by measuring protein and immune biomarkers.
Feldan Therapeutics: The company raised an undisclosed amount of venture funding from Amgen Ventures, City of Québec and Investissement Québec on February 18, 2025. Fonds de solidarite FTQ, Linearis and Genesys Capital also participated in the round. The company is an operator of a biopharmaceutical business that specializes in the development of treatments based on the intracellular delivery of therapeutics.
Noah Labs: The company raised an undisclosed amount of venture funding from European Innovation Council Fund on February 19, 2025. The company is a developer of software-based medical devices that use voice-based machine learning software for the early detection of heart failure.
x-cardiac: The company raised an undisclosed amount of venture funding from Ascenion on February 19, 2025. The company is a developer of digital biomarkers designed to predict and prevent complications after heart surgery.
|
